Work package 2

Dissemination & communication

Lead: Klinikum Nürnberg, Priv.-Doz. Dr. med. Niels Rochow

Dissemination, communication, and exploitation of results, stakeholder interaction, involvement of parents/patients in development and dissemination & exploitation processes

2.1 Data management plan (DMP) and Open Science concept
will be prepared with the help of all partners, incl. monitoring data and results, following guidelines from the EU and FAIR open science principles. Protocols, laboratory notebooks, and data (experimental, observational, images, text, numerical) will be stored at, Zendo, and GitHub with DOI in opensource file formats (e.g. blood gas analyses and numerical simulations as .csv, test protocols as .odt, or .pdf, images as .jpg, 3D design files as .stl, or .dxf, program code as .py, or .r) and referenced (public Zotero). Public sharing of data might be delayed due to IPR security consideration. Preregistration of protocols (, "protocolexchange", and definition of vocabulary and structure for documents/laboratory notebooks is mandatory. Daily data will be secured using permanent backup (OneDrive). Project management software (comindwork) reminds of data sharing, curation, and milestones. Preprints and open-access publications are deposited at Zenodo, bioRxiv, or medRxiv. Publications will be linked to corresponding original research (meta)data allowing reuse (CC-BY-NC).

2.2 Project website and publication of results
A series of communication activities will be aiming at relevant audiences (laymen and scientific) during the project. A corporate design, logo, and project website will be developed. Project-related activities will be communicated through the website, social media, newsrooms, qualitative interviews, and open-access publications in well-cited pediatric, biomedical, and other journals relevant to the consortium partners, project flyers and a roll-up. The two companies in the consortium disseminate information about the project in industry-relevant media, creating further traction in the industry for the subsequent stages of commercialisation.

2.3 Establishment of an ArtPlac society as a chapter at ELSO
A new worldwide chapter, preferably within the non-profit "Extracorporeal Life Support Organisation" (ELSO) will coordinate scientific and clinical cooperation, disseminate the project results to relevant stakeholders and to later establish a database on artificial placenta use and outcome. The chapter will be augmented by a project website.

2.4 Performing seminars and workshops at international conferences
For direct dissemination, we will offer seminars and workshops at the most European and international conferences of the respective professional societies (i.e. American and European Societies of Artificial Internal Organs (ASAIO & ESAO), Extracorporeal Life Support Organisations (ELSO, EuroELSO, Asia-Pacific ELSO), in which we explain the artificial placenta concept, offer cannulation workshops, and train interested clinicians in using ArtPlac. This will provide first-hand experience to and feedback from other clinicians, in addition to make the project and its results known in a very targeted way.

2.5 Dissemination and exploitation plan
The plan for the dissemination and exploitation of the project's results will be regularly updated. It includes the design of future animal and clinical studies for preclinical validation of the ArtPlac according to regulatory requirements for marketing approval of high-risk medical devices (class III) under the European Medical Devices Regulation.

2.6 Involvement of patients
Under the lead of the EFCNI, a patient advisory board (PAB) will be set up, consisting of a minimum of 5 European representatives with previous experience of preterm birth. Bi-annual meetings with the PAB will be conducted to update the representatives on project progress and to coordinate their input into various tasks, e.g. user design and usability of devices/interfaces, communication and dissemination etc.

All Workpackages


ArtPlac is a preclinical research project dedicated to develop an innovative technology of medical treatments for neonatal intensive care.


Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.